Free tools Windows power users keep installed
One-click scans. No signup required.
A biotech company raising capital can reduce an existing shareholder’s percentage ownership, but dilution is not automatically a loss in share price or investment value. The effect depends on how many new securities are issued, whether you can and choose to buy them, the terms of any attached warrants or convertible securities, and what the company does with the money.
Will a share issue dilute my ownership?
Usually, if a company issues new shares and you do not buy any, your percentage ownership falls. Your existing shares have not disappeared; they represent a smaller fraction of a larger total.
For example, if you own 100 shares in a company with 1,000 shares outstanding, you own 10%. If the company issues 250 new shares and you buy none, you still own 100 shares, but now hold 100 of 1,250 shares, or 8%. This arithmetic describes ownership percentage only; it does not predict the share price or your investment return.
If you buy some of the new shares, your resulting percentage depends on the number you purchase and the offering’s eligibility and allocation rules. Do not assume every capital raising gives current shareholders the right to participate. Those rights depend on the specific offer and jurisdiction.
Recommended Free Tools
#1 Best Overall
What “dilution” can mean in an offering document
Offering documents may use “dilution” to describe a different measure: the gap between the offering price and the company’s net tangible book value per share after the transaction. This accounting calculation is not the same as a reduction in your percentage ownership, and it is not a forecast that the market price will fall by that amount.
For example, BioVie Inc.’s 2026 U.S. prospectus estimated immediate net tangible book value dilution of $0.17 per share for new investors, based on an assumed combined offering price of $1.56 per share and accompanying warrant. The filing estimated net proceeds of $22.7 million under its assumptions. These are figures for that particular transaction, not typical biotech-offering outcomes. Read BioVie’s 2026 prospectus.
A separate 2026 biotech prospectus described 3,625,000 shares offered at $0.795 each, gross proceeds of $2,881,875, and estimated immediate per-share dilution of $0.80 to purchasers under the issuer’s stated net tangible book deficit calculation. That issuer-specific figure should not be generalized to other companies or offerings. Read the second issuer’s 2026 prospectus supplement.
How to calculate ownership dilution
Let S be the number of shares you own, T the company’s total shares outstanding before the offering, and N the number of new shares issued. If you buy none of the new shares:
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
- Before the offering, your ownership percentage is S ÷ T.
- After the offering, it is S ÷ (T + N).
Use the share counts specified in the issuer’s filing and check what the calculation includes. The basic post-offering count may not include securities that could later turn into shares. If you participate, add the shares you actually purchase to your holding and to the post-offering total, subject to the offer’s terms.
Look beyond the headline share count
A financing may involve more than ordinary or common shares. Shares may be bundled with warrants, or an issuer may offer pre-funded warrants, convertible debt, or other securities. Existing options, warrants and restricted stock units can also affect a future share count if they vest, are exercised or otherwise convert into shares.
BioVie’s 2026 filing describes shares with accompanying warrants and identifies outstanding options, warrants and restricted stock units excluded from some share-count assumptions. Another 2026 biotech prospectus identifies convertible notes, warrants, options and restricted stock units that may affect future share counts. The actual effects depend on each instrument’s exercise price, conversion terms, ownership blockers and other provisions; read the issuer’s own filing rather than assuming all potential shares will be issued on the same terms. BioVie’s prospectus and the second 2026 prospectus supplement show how these securities can be disclosed separately.
BioVie warns in its prospectus: “The exercise of outstanding warrants and stock options may also result in further dilution of your investment.” Treat that as a disclosure about the potential effect of those securities, not a statement that every warrant or option will be exercised.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →What to check in a financing announcement or prospectus
- Identify what is being sold. Check whether the offer consists of shares alone, shares with warrants, pre-funded warrants, convertible debt or another instrument.
- Read the economics and closing conditions. Find the offer price, maximum size, estimated net proceeds after fees, closing conditions and whether the offering is firm commitment or best efforts. Check whether a minimum amount must be raised.
- Compare share-count assumptions. Look at shares outstanding before and after the transaction, and note whether the table includes or excludes warrants, options, convertible securities and equity awards.
- Check what existing holders can do. Read any subscription rights, eligibility requirements and allocation limits. Do not infer a right to buy simply because new shares are being sold.
- Read the planned uses of proceeds. Determine whether the filing names specific uses or gives management broad discretion over the money.
- Consider a shortfall or another financing. Check what the company says may happen if it raises less than expected or needs additional capital later.
BioVie’s 2026 filing describes a best-efforts offering with no minimum amount required to close. It says actual proceeds could be significantly lower than the estimate, and that management has discretion over proceeds and may need additional funding. Those terms are specific to that offering, but they illustrate why a headline gross amount is not the same as cash the company will necessarily receive. See the filing’s offering terms and risk factors.
The second 2026 biotech prospectus lists research and development, sales and marketing, administration, working capital and capital expenditures among intended uses of proceeds, while retaining management discretion and noting future capital requirements. Such statements describe the issuer’s plans as of that filing; they do not guarantee how much capital will be raised or what results it will produce. See that prospectus supplement.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Why dilution must be weighed against the funding received
A share issue increases the number of shares, but it can also provide cash for research, clinical development, operations or other stated needs. Whether that trade-off benefits shareholders depends on the amount actually raised, transaction costs, the security terms, how the money is used and whether the funding helps the company make progress. A smaller ownership percentage does not by itself show whether the financing created or destroyed value.
The ASX and AusBiotech’s Guide to life sciences investing describes public or private share issuance as dilutive financing and states: “If the company is properly funded, the dilution will be outweighed by value creation.” That is a conditional principle, not a promise: the company must make productive use of adequate funding for value creation to offset dilution.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchRank #4
How to compare two biotech capital raisings
Do not compare offerings on the number of new shares alone. Review the same dimensions for each company, using its current filings and the assumptions stated there.
| What to compare | What to establish |
|---|---|
| Price and size | Offer price, maximum size and expected net proceeds after fees; distinguish gross from net proceeds. |
| Closing conditions | Whether the transaction is firm commitment or best efforts, whether a minimum raise is required and what conditions must be met. |
| Security package | Shares, warrants, pre-funded warrants, convertible instruments and their specific terms. |
| Share count | Basic post-offering shares and the filing’s fully diluted assumptions, including securities excluded from particular calculations. |
| Existing-holder access | Any subscription rights, eligibility rules and allocation terms. |
| Use of funds and financing needs | Stated uses, management discretion, possible shortfalls and whether additional funding may be needed. |
| Company progress | The scientific or clinical milestones the funding is intended to support and the issuer’s financing needs in current filings. |
These factors help explain the financing’s structure and possible consequences; they do not establish that one offer is attractive. That assessment also requires current issuer-specific facts and valuation work. Prospectuses describe terms, assumptions and risks rather than guaranteeing that an offering will close or that the proceeds will be used successfully.
The examples above are U.S. SEC filings from 2026, while the ASX/AusBiotech guide provides life-sciences investing context. Offering mechanics and securities rules differ across markets. For any company you are considering, check the current filing, offering status, share count, security terms and applicable exchange rules.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →
